End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28,400 KRW | +3.27% | +5.38% | +9.86% |
2023 | NeoPharm CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
2019 | NeoPharm CO., LTD. announced that it has received KRW 31.970667276 billion in funding | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Its low valuation, with P/E ratio at 10.15 and 7.74 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company shows low valuation levels, with an enterprise value at 1849.81 times its sales.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The group usually releases upbeat results with huge surprise rates.
Ratings chart - Surperformance
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.86% | 163M | - | ||
-2.05% | 259B | B- | ||
+18.81% | 20.66B | B+ | ||
0.00% | 19.04B | - | - | |
+17.33% | 12.68B | A- | ||
-13.77% | 9.25B | A- | ||
+23.03% | 8.07B | B+ | ||
+11.07% | 6.01B | B | ||
-12.20% | 3.98B | B+ | ||
-16.08% | 3.87B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- A092730 Stock
- Ratings NeoPharm CO., LTD.